<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398541</url>
  </required_header>
  <id_info>
    <org_study_id>0954A-322</org_study_id>
    <secondary_id>MK0954A-322</secondary_id>
    <secondary_id>2006_048</secondary_id>
    <nct_id>NCT00398541</nct_id>
  </id_info>
  <brief_title>Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)</brief_title>
  <official_title>Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Evaluate the antihypertensive and neuroprotective effects of Hyzaar(R) in elderly subjects in
      comparison with Natrilix(TM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2005</start_date>
  <completion_date type="Actual">June 1, 2007</completion_date>
  <primary_completion_date type="Actual">April 10, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychological tests and blood pressure after treatment of 12 weeks</measure>
    <time_frame>after treatment of 12 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan potassium (+) hydrochlorothiazide</intervention_name>
    <description>losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25</description>
    <other_name>MK954A</other_name>
    <other_name>Hyzaar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ACEi or ARB naive or not taking ACEi or ARB concurrently for at least one month before
             the run-in period

          -  Be able to carry out his or her own daily activity

          -  - Be at least 50 years old at inclusion in the study Be diagnosed with mild to
             moderate hypertension, treated or untreated

          -  Literate

          -  Not taking any cognitive-enhanced agent at baseline

          -  Present with a memory complain ( spontaneous or informed by caregiver)

        Exclusion Criteria:

          -  Congestive heart failure with NYHA class &gt;2

          -  Renal failure or renal insufficiency with serum creatinine &gt;1.4mg/dl

          -  chronic severe liver disease with abnormal GPT and GOT &gt;2 times of upper normal limits

          -  Diagnosed with major depression when entering the study

          -  Foreign language as his or her mother tongue so that the test results will not be
             reliable

          -  History of stroke or transient ischemic attack (stroke is defined as focal
             neurological sign progressing stepwise)

          -  Hypersensitive to the active ingredient and any other component of losartan potassium
             and indapamide tablets

          -  Major hearing loss/deafness and/or major visual impairment/blindness preventing from
             performing the tests

          -  Myocardial infarction within the past 6 months

          -  Single functioning kidney

          -  Anuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

